Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Fecal Microbiota (Rebyota)

decorative image of the issue cover

Published April 2, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses fecal microbiota (Rebyota), 150 mL, rectal suspension.
  • Indication: For the prevention of recurrence of Clostridioides difficile infection (CDI) in adults following antibiotic treatment for recurrent CDI.
  • Fecal microbiota (Rebyota) is not indicated for the treatment of CDI.